Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-04691502 and Gedatolisib in Recurrent Endometrial Cancer
NCT01420081Phase 2Terminated
- Sponsor
- Pfizer
- Start
- Jan 2012
- Primary completion
- Apr 2014
- Modality
- Small Molecules
- Countries
- 8
01
Overview
A Phase 2 trial of PF-04691502, gedatolisib in endometrial cancer (EC), sponsored by Pfizer. Started Jan 2012; status: terminated.
02
Drugs
PF-04691502gedatolisib
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT01420081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01420081.